Efficacy and safety of moxibustion in female infertility patients undergoing in vitro fertilization and embryo transfer: A systematic review protocol (2024)

Abstract

Introduction:

The purpose of this paper is to evaluate the efficacy and safety of moxibustion in infertility females/women undergoing in vitro fertilization and embryo transfer (IVF-ET).

Methods and analysis:

We will electronically search PubMed, Medline, Embase, Web of Science, the Cochrane Central Register of Controlled Trial, China National Knowledge Infrastructure, China Biomedical Literature Database, China Science Journal Database, and Wan-fang Database from their inception. Also, we will manually retrieve other resources, including reference lists of identified publications, conference articles, and grey literature. The clinical randomized controlled trials or quasi-randomized controlled trials related to moxibustion in female infertility patients undergoing IVF-ET will be included in the study. The language is limited to Chinese and English. Research selection, data extraction, and research quality assessment will be independently completed by 2 researchers. Data were synthesized by using a fixed effect model or random effect model depend on the heterogeneity test. The clinical total effective rate and the clinical pregnancy rate will be the primary outcomes. Ovulation rate, endometrial thickness, hormone level, traditional Chinese medicine (TCM) Syndrome Integral Scale and the adverse event will also be assessed as secondary outcomes. RevMan V.5.3 statistical software will be used for meta-analysis, and the level of evidence will be assessed by Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Continuous data will be expressed in the form of weighted mean difference or standardized mean difference with 95% confidence intervals (CIs), while dichotomous data will be expressed in the form of relative risk with 95% CIs.

Results:

This study will provide a high-quality comprehensive evaluation of the efficacy and safety of moxibustion in the treatment of female infertility patients undergoing IVF-ET.

Conclusion:

This review will provide evidence to judge for judging whether moxibustion is effective in treating female infertility patients undergoing IVF-ET.

Systematic review registration:

PROSPERO, CRD42019135593

Keywords: female infertility, in vitro fertilization and embryo transfer, moxibustion, protocol, systematic review

1. Introduction

Infertility refers to the cohabitation of adult men and women with a normal and regular sexual life history of >1 year, in the absence of any contraceptive measures and women failed to be pregnant.^[1,2] Its global incidence ranges from 9% to 18%.^[3] Studies have shown that there are 186 million people worldwide suffering from infertility, and the incidence varies from region to region, but it is high in developing countries.^[4,5] Infertility is often divided into primary and secondary types in clinic,¹ and the secondary infertility is the most common female infertility in the world.^[6] It is a complex interaction of multiple factors, including functional, biological, and environmental impacts.^[7,8] The main causes of female infertility include reproductive system diseases, abnormal immune function, psychological factors, cultural level, and age of pregnancy.^[5,9,10] Among them, the reproductive system diseases such as the polycystic ovary syndrome (PCOS), tubal obstruction, tuberculosis, and other infections caused by pelvic inflammation, endometriosis, and so on are the main complaints from infertility females.^[11–13] In addition, up to 20% of infertile couples cannot explain the cause of their infertility.^[14]

Currently, the treatment of infertility in western medicine mainly includes reproductive drugs, surgery, or assisted reproductive technology (ART) including in vitro fertilization.^[15–17] ART is a new medical application technology. It refers to the in vitro dispose of the human oocyte, sperm or embryo, including all treatments or procedures for initiating a pregnancy.^[18] Its main contents consist of in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), gamete and embryo cryopreservation, gene diagnosis before embryo implantation, and gene screening before embryo implantation.^[18,19] While these treatments have been a boon for infertile patients, the low pregnancy rate, high cost, long cycle, and repeated transplantation failure of IVF technology increase the enormous financial burden and mental pressure on patients.^[20–25] These results directly lead to many infertile couples abandoning treatment,^[26] or turning to complementary alternative medicine (CAM).^[27–29]

Acupuncture and moxibustion, as one of important CAM, which has been applied to treating gynecological diseases for thousands of years, has been welcomed by many infertile couples in recent years.^[30–33] Moxibustion, as a treatment of acupuncture and moxibustion, refers to the ignition of moxa velvet or stick, then it acts on the corresponding acupoints for burning or fumigation, relying on the role of heat and medicine to achieve the role of disease prevention and treatment. TCM theory holds that moxibustion has the functions of warming and dredging channels and collaterals, regulating qi and blood, dispelling cold and relieving pain, preventing and treating diseases, and strengthening health. It is often used in gynecologic uterine cold caused by infertility, menstrual pain, and metrorrhagia.^[34] Modern medical research suggest that moxibustion can improve ovarian function by inhibiting apoptotic events of naturally aging ovaries and enhancing antioxidant defense ability.^[35] The stimulation of meridian acupoints by its physical thermo-thermal characteristics and chemical composition of tar from Artemisia argyi leaves can activate the self-discipline movement of blood vessels, accelerate blood flow, improve blood circulation, and accelerate local blood circulation.^[36,37] Thus, improving ovarian artery blood supply and increasing diastolic blood perfusion can significantly improve ovulation rate and pregnancy rate.^[38] Also, animal experiments have found that moxibustion can reduce the expression of p-PI3K, p-Akt, and p-mTOR in rat ovaries. It is suggested that moxibustion may improve ovarian hormone level and inflammatory response by inhibiting the PI3K/Akt/mTOR signaling pathway.^[39] Therefore, based on the above experiments, moxibustion has been widely applied to treat female infertility caused by PCOS,^[40] premature ovarian failure,^[41] tubal obstruction,^[42,43] and so on. In recent years, there are more and more studies on the treatment of female infertility by moxibustion. However, to the best of our knowledge, there is no systematic review (SR) at home and abroad to evaluate the efficacy and safety of moxibustion in this field. Therefore, we intend to perform a SR evaluation on the efficacy and safety of moxibustion for female infertility patients through strict review method, hoping to provide a convincing conclusion.

2. Methods and analysis

2.1. Design and registration of the review

Our SR has been registered on PROSPERO (registration number is CRD42019135593) and the protocol is designed strictly in coordinate with the preferred reporting items of the systematic review and meta-analysis protocol (PRISMA-P).^[44] The PRISMA Guidelines and the Cochrane Handbook will be used for the studies we evaluate for inclusion. In addition, bias risk analysis and heterogeneity analysis will also be used in our SR. Subgroup analysis and sensitivity analysis will be further carried out when necessary.

2.2. Inclusion criteria

2.2.1. Type of study

We will include randomized controlled clinical trials and quasi-randomized controlled trials. However, studies that used incorrect randomization methods (such as flipping a coin) would not be included. Any other type of literature will be excluded, including moxibustion literature as a non-primary intervention, retrospective research literature, repeated publications, conference abstracts, literature that cannot extract data, case reports, and bibliometric studies. The language limit for searching literature will be limited to Chinese and English due to the language limitation of our researchers.

2.2.2. Types of participants

The study will included women diagnosed with infertility and receiving IVF-ET, ages ranging from 14 to 60, regardless of race, educational level, source of cases, and cause of illness. In addition, repeated IVF failures will also be included. Participants with other serious diseases, such as heart disease, liver disease, kidney disease, or cancer (especially ovarian and breast cancer) will be excluded from the trial.

2.2.3. Types of interventions

The intervention measures should adopt moxibustion alone or moxibustion combined with other methods (exclusion of combination of acupuncture and moxibustion) to treat female infertility, while the control group was treated with non-moxibustion therapy, blank control group, or placebo moxibustion (such as moxa stick not ignited).

2.2.4. Types of outcomes

The main outcomes will be the total effective rate and the clinical pregnancy rate, total effective rate = (total effective number)/total number × 100%, clinical pregnancy rate = (clinical pregnancy number)/total number of pregnancies × 100%.

2.3. Data sources and search methods

2.3.1. Electronic searches

We will use computers to search PubMed, Medline, Embase, Web of Science and the Cochrane Central Register of Controlled Trials. Besides, China National Knowledge Infrastructure, China Biomedical Literature Database, China Science Journal Database, and Wan-fang Database will also be collected by our researchers. All databases will be searched from the date of creation to May 31, 2019. The following search terms will be used: infertility, female infertility, polycystic ovary syndrome infertility, premature ovarian failure infertility, tubal infertility, ovulation barrier infertility; moxibustion, moxa leaf, moxa velvet, moxa stick, moxa cone, moxibustion box, ginger-separated moxibustion, dragon moxibustion (Du meridian moxibustion), cake-separated moxibustion, heat-sensitive moxibustion, medicinal moxibustion, sparrow pecking moxibustion, suspension moxibustion; in vitro fertilization, embryo transfer, IVF-ET. The sample search strategy in Table 1 will be used for PubMed. This search strategy will be slightly modified and used in several other databases.

Table 1.

Search strategy used in PubMed.

Open in a new tab

2.3.2. Searching other resources

For more experiments, we will search for lists of relevant references. We will search the existing SRs of PubMed and Chorane library related to our research topics, and then search their bibliographies for more research. Besides, we will search a reference list to identify published journals, books, conference articles, and gray literature related to the research topic.

2.4. Data collection and management

After completing all the electronic search work, the result will be imported to Noteexpress software Version 2.6.1 (Aegean Sea software company, Beijing, China) in the same text format, and repeated research will be eliminated by software. Two reviewers (LY and WL) independently complete the screening of documents and then cross-check to determine the final inclusion of documents. In the first stage, all documents after software review will be screened for title, summary, and keywords to determine which documents meet the selection criteria. In the second stage, we will evaluate the full text of the remaining studies and determine whether it meets the SRs criteria. The research excluded after reading the full text will also be documented, and the reasons for exclusion will be recorded. When differences arise in this process, we will invite third parties (ZQH) to arbitrate. The research flow chart is shown in Fig. 1.

2.5. Data extraction and analysis

Two researchers (LY and WL) will independently complete data extraction and analysis, and then cross-check the results. In this process, a third author (ZQH) will be invited to resolve any disagreement between the 2 persons. We will produce an Excel spreadsheet to extract literature data, including the first author, country, year of publication, patient characteristics, course of the disease, number of studies, interventions, course of the intervention, outcome indicators, main conclusions, conflicts of interest, recurrence rate, acupoint selection, and adverse events. If the data reported in the document is insufficient, we will contact the author of the experiment for consultation and resolution. However, if we fail to contact the author, the document will be excluded.

2.6. Assessment of risk of bias in the included studies

The Cochrane Manual V.5.1.0 tool will be used to assess the risk of bias for each included study. The evaluation includes random sequence generation, allocation sequence hiding, blind evaluation, incomplete result data, selective result report, and other bias sources. The assessment results will be divided into 3 levels: low risk, high risk, and uncertainty risk.

2.7. Assessment of heterogeneity

We will test the heterogeneity of data by calculating the value of I² statistics and chi-squared test. When P > .1, I² < 50%, it is considered that there is no great heterogeneity in the study. However, when P < .1, I² > 50%, it is considered that the study has significant statistical heterogeneity. At this very moment, the subgroup stratification analysis will be further carried out to explore the possible sources of heterogeneity.

2.8. Assessment of reporting biases

Funnel chart will be used to assess reporting bias. When the number of studies included exceeds 10 trials, we will use Egger method^[45] to test funnel chart asymmetry. If the funnel chart is evenly distributed, it indicates that there is no publication bias.

2.9. Data synthesis

We will use RevMan V.5.3 to perform data synthesis. The dichotomous data will be analyzed by relative risk (RR), and the continuous data will be analyzed by the mean difference (MD) or standardized mean difference (SMD). Specific expressions are as follows: when the I² test is <50%, the fixed effect model is used to synthesize the data. If the I² test is between 50% and 75%, the random effect model is used to synthesize the data. If the I² test is >75%, we will conduct a subgroup analysis to analyze possible causes. All data will be analyzed with 95% CIs. If data cannot be synthesized, we will use descriptive analysis to solve this problem.

2.10. Subgroup analysis

In the case of high heterogeneity, we will determine the source of heterogeneity by subgroup analysis according to the different combined intervention methods, different treatment courses, different amount of moxibustion, different single moxibustion treatment time, and other different influence factors of female infertility.

2.11. Sensitivity analysis

We will conduct a sensitivity analysis to test the recklessness of major decisions in the review process. The main contents of the analysis include the impact of method quality, sample size, and missing data on the study. The meta-analysis will be reused and poor quality research will be excluded. The results will be compared and discussed according to the results.

2.12. Grading the quality of evidence

The quality of SRs will be evaluated by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE).^[46,47] Five downgrading factors including risk of bias, inconsistency, indirectness, imprecision, and publication bias will be assessed. The assessment results will be divided into 4 levels: high, moderate, low or very low.

3. Discussion

Female infertility is a complex disease with different pathogenic factors. According to WHO report, infertility in the 21st century will become the third-largest disease after cardiovascular, cerebrovascular diseases, and tumors.^[48] In addition, the risk of female infertility developing into mental illness is also increasing.^[49] At present, many patients and some obstetricians and gynecologists are not satisfied with the treatment results. With the development of CAM, moxibustion, as a traditional method of acupuncture and moxibustion, is widely used in the treatment of gynecological diseases because of its simple operation, long curative effect, low cost, easy acceptance, without needling pain, and no obvious side effects. Nevertheless, there is no English and Chinese publication of SR related to moxibustion for female infertility. This study will collect evidence comprehensively, extract and analyze the data, and draw reasonable and objective conclusions, hoping to provide an evidence-based basis for moxibustion treatment of female infertility and provide more useful information for medical staff and better advice for patients.

Author contributions

Conceptualization: Tinghui Hou.

Data curation: Ying Liu, Lu Wang.

Formal analysis: Qianhua Zheng.

Funding acquisition: Ying Li.

Investigation: Tinghui Hou.

Methodology: Xiumei Feng.

Project administration: Ying Li.

Supervision: Qianhua Zheng.

Writing – original draft: Tinghui Hou.

Writing – review and editing: Qianhua Zheng.

Footnotes

Abbreviations: and Evaluation, ART = assisted reproductive technology, CAM = complementary alternative medicine, CIs = confidence intervals, Development, GRADE = Grading of Recommendations Assessment, ICSI = intracytoplasmic sperm injection, IVF-ET = in vitro fertilization and embryo transfer, MD = mean difference, PCOS = polycystic ovary syndrome, PRISMA-P = preferred reporting items for systematic reviews and meta-analysis protocol, RR = relative risk, SMD = standardized mean difference, SR = systematic review, TCM = traditional Chinese medicine.

How to cite this article: Hou T, Zheng Q, Feng X, Liu Y, Wang L, Li Y. Efficacy and safety of moxibustion in female infertility patients undergoing in vitro fertilization and embryo transfer. Medicine. 2019;98:44(e17560).

Ethics and dissemination: The protocol of the SR does not require ethical approval because it does not involve humans. We will publish this article in peer-reviewed journals and presented at relevant conferences.

This study was carried out with the support of the project supported by the Ministry of Science and Technology of China. “Acupuncture and moxibustion for perimenopausal syndrome and functional constipation: an international multicenter randomized controlled clinical trial” (grant numbers 2012BAI24B01).

The authors have no conflicts of interest to disclose.

References

[1].Zegers-Hochschild F, Adamson D, Dyer S, et al. The international glossary on infertility and fertility care. Hum Reprod2017;32:1786–801. [DOI] [PMC free article] [PubMed] [Google Scholar]
[2].Practice Committee of American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril2013;99:63. [DOI] [PubMed] [Google Scholar]
[3].Aghajanova L, Hoffman J, Mok-Lin E, et al. Obstetrics and gynecology residency and fertility needs. Reprod Sci2017;24:428–34. [DOI] [PubMed] [Google Scholar]
[4].Inhorn MC, Patrizio P.Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Hum Reprod Update2015;21:411–26. [DOI] [PubMed] [Google Scholar]
[5].Vander-Borght M, Wyns C.Fertility and infertility: definition and epidemiology. Clin Biochem2018;62:2–10. [DOI] [PubMed] [Google Scholar]
[6].Nachtigall RD.International disparities in access to infertility services. Fertil Steril2006;85:871–5. [DOI] [PubMed] [Google Scholar]
[7].Yazdani A.Surgery or in vitro fertilisation: the simplicity of this question belies its complexity. Aust N Z J Obstet Gynaecol2017;57:676–8. [DOI] [PubMed] [Google Scholar]
[8].Sarapik A, Haller-Kikkatalo K, Utt M, et al. Serum anti-endometrial antibodies in infertile women-potential risk factor for implantation failure. Am J Reprod Immunol2010;63:349–57. [DOI] [PubMed] [Google Scholar]
[9].Li JY, Jiang LL, Feng ZY, et al. Research progress on factors affecting female infertility [Chinese]. Med Rev2018;24:4858–63. [Google Scholar]
[10].Rezvani M, Shaaban AM.Fallopian tube disease in the nonpregnant patient. Radiographics2011;31:527–48. [DOI] [PubMed] [Google Scholar]
[11].Kowalcek I, Wihstutz N, Buhrow G, et al. Subjective well-being in infertile couples. J Psychosom Obstet Gynaecol2001;22:143–8. [DOI] [PubMed] [Google Scholar]
[12].Corbett S, Morin-Papunen L.The polycystic ovary syndrome and recent human evolution. Mol Cell Endocrinol2013;373:39–50. [DOI] [PubMed] [Google Scholar]
[13].Vercellini P, Vigano P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol2014;10:261–75. [DOI] [PubMed] [Google Scholar]
[14].Pandian Z, Gibreel A, Bhattacharya S.In vitro fertilisation for unexplained sub-fertility. Cochrane Database Syst Rev2015. CD003357. [DOI] [PMC free article] [PubMed] [Google Scholar]
[15].Carneiro MM.What is the role of hysteroscopic surgery in the management of female infertility? A review of the literature. Surg Res Pract2014;2014:105412. [DOI] [PMC free article] [PubMed] [Google Scholar]
[16].Yu X, Ruan J, He LP, et al. Efficacy of growth hormone supplementation with gonadotrophins in vitro fertilization for poor ovarian responders: an updated meta-analysis. Int J Clin Exp Med2015;8:4954–67. [PMC free article] [PubMed] [Google Scholar]
[17].Szamatowicz M.Assisted reproductive technology in reproductive medicine-possibilities and limitations. Ginekol Pol2016;87:820–3. [DOI] [PubMed] [Google Scholar]
[18].Zegers-Hochschild F, Adamson GD, de Mouzon J, et al. The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary on ART terminology, 2009. Hum Reprod2009;24:2683–7. [DOI] [PubMed] [Google Scholar]
[19].Fu JL, Ding QX, Huang Y.Research progress of human assisted reproduction technology.journal of local surgery [Chinese]. J Reg Anat Oper Surg2019;28:418–21. [Google Scholar]
[20].Wu AK, Odisho AY, Washington SL, et al. Out-of-pocket fertility patient expense: data from a multicenter prospective infertility cohort. J Urol2014;191:427–32. [DOI] [PubMed] [Google Scholar]
[21].Freeman MP, Toth TL, Cohen LS.Assisted reproduction and risk of depressive relapse: considerations for treatment. Ann Clin Psychiatry2013;25:283–8. [PubMed] [Google Scholar]
[22].Covington SN, Hammer Burns L.Infertility Counseling. 2nd ed2006;New York: Cambridge University Press, 1–658. [Google Scholar]
[23].Mahajan NN, Turnbull DA, Davies MJ, et al. Changes in affect and state anxiety across an in vitro fertilization/intracytoplasmic sperm injection cycle. Fertil Steril2010;93:517–26. [DOI] [PubMed] [Google Scholar]
[24].Xu H, Ouyang N, Li R, et al. The effects of anxiety and depression on in vitro fertilisation outcomes of infertile Chinese women. Psychol Health Med2017;22:37–43. [DOI] [PubMed] [Google Scholar]
[25].Knoll N, Schwarzer R, Pfüller B, et al. Transmission of depressive symptoms: a study with couples undergoing assisted-reproduction treatment. Eur Psychol2009;14:7–17. [Google Scholar]
[26].Brandes M, Van Der Steen JOM, Bokdam SB, et al. When and why dosubfertile couples discontinue their fertility care? A longitudinal cohort study in a secondary care subfertility population. Hum Reprod2009;24:3127–35. [DOI] [PubMed] [Google Scholar]
[27].Xia J, Inagaki1 Y, Zhang J, et al. Chinese medicine as complementary therapy for female infertility. Chin J Integr Med2016;23:245–52. [DOI] [PubMed] [Google Scholar]
[28].Jiang D, Li L, Zeng BY.Treatment of Chinese herbal medicine for female infertility. Int Rev Neurobiol2017;135:233–47. [DOI] [PubMed] [Google Scholar]
[29].Zhang Y, Fu Y, Han F, et al. The effect of complementary and alternative medicine on subfertile women with in vitro fertilization. Evid Based Complement Alternat Med2014;2014:419425. [DOI] [PMC free article] [PubMed] [Google Scholar]
[30].Witt CM, Pach D, Brinkhaus B, et al. Safety of acupuncture: results of a prospective observational study with 229,230 patients and introduction of a medical information and consent form. Forsch Komplementmed2009;16:91–7. [DOI] [PubMed] [Google Scholar]
[31].Shen C, Wu M, Shu D, et al. The role of acupuncture in vitro fertilization: a systematic review and meta-analysis. Gynecol Obstet Invest2015;79:1–2. [DOI] [PubMed] [Google Scholar]
[32].Hullender Rubin LE, Opsahl MS, Taylor-Swanson L, et al. Acupuncture and in vitro fertilization: a retrospective chart review. J Altern Complement Med2013;19:637–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
[33].Zhou J, Qu F.Treating gynecological disorders with Traditional Chinese Medicine: a review. Afr J Tradit Complement Altern Med2009;6:494–517. [DOI] [PMC free article] [PubMed] [Google Scholar]
[34].Liang SY.Modern Literature Study on Acupuncture and Moxibustion Treatment of Ovulatory Infertility [Doctor's thesis]. Guangzhou, China: Guangzhou University of Traditional Chinese Medicine; 2015. [Google Scholar]
[35].Yang X, Wang W, Zhang Y, et al. Moxibustion improves ovary function by suppressing apoptosis events and upregulating antioxidant defenses in natural aging ovary. Life Sci2019;229:166–72. [DOI] [PubMed] [Google Scholar]
[36].Li WJ, Wang AD, Cao XW, et al. Study on abdominal infrared thermography characteristics of primary dysmenorrhea treated by moxibustion at diji point [Chinese]. Shanghai J Acupuncture Moxibustion2012;31:659–61. [Google Scholar]
[37].Kawakita K, Shinbara H, Imai K, et al. How do acupuncture and moxibustion act?- Focusing on the progress in Japanese acupuncture research. J Pharmacol Sci2006;100:443–59. [DOI] [PubMed] [Google Scholar]
[38].Nelson PL, Beck A, Cheng H.Transient receptor protrins illuminated: current views on TRPs and disease. Vet J2011;187:153–64. [DOI] [PubMed] [Google Scholar]
[39].Zhang CR, Deng JL, Zhu WN, et al. PI3K/Akt/mTOR signaling pathway mediates moxibustion to improve premature ovarian failure in rats [Chinese]. Acupuncture Res2018;43:75–9. [DOI] [PubMed] [Google Scholar]
[40].Kwon CY, Lee B, Park KS.Oriental herbal medicine and moxibustion for polycystic ovary syndrome. A meta-analysis. Medicine (Baltimore)2018;97:e12942. [DOI] [PMC free article] [PubMed] [Google Scholar]
[41].Jiang DS, Zhang YC, Wu XL, et al. Observation on curative effect of Ginger-separated Moxibustion at Baliao acupoint combined with Bushen Huoxue Recipe on ovarian reserve function decline [Chinese]. Zhongguo Zhen Jiu2017;37:1057–60. [DOI] [PubMed] [Google Scholar]
[42].Lu J, Liu RT, Tu XY.Thermosensitive moxibustion combined with Huoxue Quyu prescription in the treatment of 50 cases of fallopian tube infertility [Chinese]. Jiangxi Trad Chin Med2016;47:67–9. [Google Scholar]
[43].Liu YL, Pan LZ, Wang Y.Effect of heat-sensitive moxibustion combined with Acupoint Injection on endometrial receptivity of infertility patients with hydrosalpinx after hysteroscopy [Chinese]. Zhongguo Zhen Jiu2018;38:22–6. [DOI] [PubMed] [Google Scholar]
[44].Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols(PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical research ed)2015;350:g7647. [DOI] [PubMed] [Google Scholar]
[45].Deeks JJ, Higgins JPT, Altman DG, et al. Analyzing data and undertaking meta-analysis. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]The Cochrane Collaboration; 2011. [Google Scholar]
[46].Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ2008;336:1106–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
[47].Van de Griendt EJ, Tuut MK, de Groot H, et al. Applicability of evidence from previous systematic reviews on immunotherapy in current practice of childhood asthma treatment: a GRADE (Grading of Recommendations Assessment, Development, and Evaluation) systematic review. BMJ Open2017;7:e016326. [DOI] [PMC free article] [PubMed] [Google Scholar]
[48].Rostami Dovom M, Ramezani Tehrani F, Abedini M, et al. A population-based study on infertility and itsinfluen-cing factors in four selected provinces in Iran (2008–2010). Iran J Reprod Med2014;12:561–6. [PMC free article] [PubMed] [Google Scholar]
[49].Agostini F, Monti F, Andrei F, et al. Assisted reproductive technology treatments and quality of life: a longitudinal study among subfertile women and men. J Assist Reprod Genet2017;34:1307–15. [DOI] [PMC free article] [PubMed] [Google Scholar]